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Although it is recognized that patients with major depressive disorder (MDD) are at 
increased risk of developing cardiovascular disease (CVD) the mechanisms responsible 
remain unknown. Endothelial dysfunction is one of the first signs of CVD. Using two 
techniques, flow-mediated dilatation in response to reactive hyperemia and laser Doppler 
velocimetry with iontophoresis, we examined endothelial function in the forearm before 
and after serotonin-specific reuptake inhibitor (SSRI) treatment in 31 patients with MDD. 
Measurement of intercellular adhesion molecule-1, vascular cell adhesion molecule-1, 
soluble P-selectin, and noradrenaline in plasma was also performed. Prior to treatment, 
markers of endothelial and vascular function and platelet reactivity were within the nor-
mal range. Following SSRI therapy (95 ± 5 days) symptoms of depression were reduced 
(paired difference between pre- and post-treatment Hamilton rating −18 ± 1, P < 0.001) 
with 19 patients recovered and 4 remitted. There occurred no significant change in 
markers of endothelial or vascular function following SSRI therapy. The improvement 
in Hamilton depression rating in response to therapy could be independently predicted 
by the baseline arterial plasma noradrenaline concentration (r2 = 0.36, P = 0.003). In 
this cohort of patients with MDD, SSRI therapy did not influence endothelial function 
or markers of vascular or platelet reactivity. Patient response to SSRI therapy could be 
predicted by the initial circulating level of noradrenaline, with noradrenaline levels being 
lower in responders.
Keywords: affective disorders, antidepressants, major depressive disorder, cellular adhesion molecules, 
P-selectin, cardiovascular disease
inTrODUcTiOn
The link between cardiovascular disease (CVD) development and major depressive disorder (MDD) 
is well described (1–3). Importantly, the detrimental effect of MDD on CVD is already evident in 
young individuals (4). Although the mechanisms linking MDD and CVD development remain to 
be unequivocally determined previous studies have provided some evidence of sympathetic nervous 
activation, endothelial dysfunction, and increased platelet reactivity in patients with MDD. Together, 
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or in concert with other lifestyle factors, these physiological pro-
cesses may provide an environment that in depressed individuals 
may predispose them to increased CVD risk.
Endothelial dysfunction is one of the earliest signs of CVD 
development. Studies investigating endothelial dysfunction in 
patients with MDD have yielded conflicting results. Symptoms 
of anxiety and depression in women, which were measured before 
and after menopause, were associated with endothelial dysfunc-
tion 5 years post-menopause (5). In young adults with untreated 
depression, Rajagopalan and colleagues also reported endothelial 
dysfunction in patients with depression (6), whereas Garcia et al. 
noted that reduced concentration of nitric oxide metabolites in 
plasma were not associated with impaired endothelial function 
in young, drug-naive patients with first onset depression (7). 
Although endothelial function was shown to be improved in 
patients with coronary heart disease and symptoms of depres-
sion following 20  weeks of sertraline treatment (8), a shorter 
period of therapy with either of these, sertraline, fluoxetine, or 
paroxetine, in women with no history of CVD was associated 
with no improvement in endothelial function (9). Given the 
equivocal nature of these results, in this study, we aimed to 
examine endothelial function, in otherwise healthy patients 
with MDD, prior to and following serotonin-specific reuptake 
inhibitor (SSRI) treatment using two different techniques, flow-
mediated dilatation in response to reactive hyperemia to examine 
endothelial function in large vessels in the forearm, and, in small 
vessels, laser Doppler velocimetry (LDV) with iontophoresis of 
acetylcholine (ACh) and sodium nitroprusside (SNP) (10). Blood 
samples were obtained to examine markers of vascular function 
and platelet reactivity.
MaTerials anD MeThODs
This study formed part of a larger study assessing cardiovascular 
risk prior to and following SSRI treatment in patients with MDD 
(11, 12). Data obtained from 31 patients (19 females and 12 males) 
with MDD forms the basis of this report. The Alfred Hospital 
Ethics Committee approved the research protocol and participants 
gave written informed consent prior to commencing the study. 
Participants were recruited via local advertisement or following 
referral from general physicians. Following initial telephone 
screening, subjects underwent a physical examination. Exclusion 
criteria included comorbid medical conditions, such as pre-
existing heart disease, type 1 diabetes, medicated hypertension, 
epilepsy, bleeding disorders, alcohol/drug dependence, infectious 
blood diseases, comorbid psychotic disorders, eating disorders, 
mental retardation, dementia and personality disorders, and the 
use of any medication including anti-coagulants. Patients were 
either newly diagnosed or currently untreated after a relapse and 
had not been taking antidepressants, including herbal remedies, 
or benzodiazepines for at least 4 weeks prior to the study (5 weeks 
if they had been on fluoxetine). No patients presented with psy-
chotic symptoms. Patients having previously failed to respond 
to treatment with a SSRI at the maximum tolerated dose for at 
least 4 weeks were not included in the study. Investigations were 
performed at baseline in unmedicated patients and following at 
least 12 weeks SSRI therapy (n = 22 citalopram, n = 4 sertraline, 
n = 3 fluvoxamine, and n = 2 fluoxetine).
All participants had a psychiatric interview using the full Mini 
International Neuropsychiatric Interview (MINI) to ensure that 
they met DSM-IV diagnostic criteria for MDD. Hamilton depres-
sion (HAM-D) scale and Beck depression inventory (BDI-II) 
were used to monitor progress. Standard cut offs for recovery 
and remission, that is, 50% drop in HAM-D and BDI-II score 
for remission, and a score of <8 in HAM-D and BDI-II to signify 
recovery, were used. Spielberger’s state and trait anxiety invento-
ries were used to assess the level of underlying anxiety. Eligibility 
for entry was determined by HAM-D > 18, BDI-II > 18, and major 
depression diagnosis on MINI and deemed to have a significant 
major depression as the primary illness at psychiatric interview. 
Only patients diagnosed on the MINI with major depression or 
major depression with melancholia according to ICD 10 and 
DSM-IV criteria were included. Patients with comorbid panic 
or anxiety disorders were included in the study, if the primary 
diagnosis was depression and any panic/anxiety was secondary 
to their depression.
Measurement of endothelial function was assessed by strain 
gage plethysmography of the forearm and LDV with direct current 
iontophoresis. Strain gage plethysmography measures forearm 
blood flow in response to reactive hyperemia in resistance vessels 
(13). In the current study, venous occlusion pressure was set at 
50 mmHg, while blood flow to the wrist and hand were excluded 
by application of a pediatric blood pressure cuff to the wrist raised 
to suprasystolic blood pressure of 200 mmHg. The venous cuff, 
positioned around the upper dominant arm, was plugged into an 
automatic pneumatic inflator (Hokanson E20 rapid cuff inflator, 
Washington, DC, USA). Changes in forearm volume were meas-
ured using an indium–gallium filled double-stranded strain gage 
(Hokanson, Washington, DC, USA) placed around the widest 
part of the forearm, connected to a plethysmograph (Hokanson 
EC6, Washington, DC, USA). Baseline flow measurements were 
obtained by averaging three to five measurements of 10-s cycles 
of successive inflation/deflation of the upper arm cuff. Arterial 
blood flow occlusion was achieved by inflating the upper arm 
cuff to 150  mmHg, or approximately 20  mmHg above systolic 
blood pressure, for 5 min (termed reactive hyperemia). Following 
reactive hyperemia, the wrist cuff was once again inflated to sup-
raphysiological levels, and the upper cuff was suddenly deflated 
and the cycles of venous compressions immediately resumed 
until blood flow returned to baseline levels. As a positive control, 
300  μg glyceryl trinitrate [GTN (Sigma, VIC, Australia)] was 
administered sublingually before 5-min reactive hyperemia was 
initiated. Glyceryl trinitrate is a nitric oxide donor; therefore, 
it is used as an endothelium-independent marker, providing a 
comparison with endothelium-dependent forearm blood flow. 
Data were acquired, recorded, and analyzed using MacLab/2e 
(ADInstruments, NSW, Australia), and the computer program 
Chart v4.1.2 (Chart for Windows, ADInstruments). Results were 
expressed as % change from baseline.
Subcutaneous vascular reactivity was measured using LDV 
with direct current iontophoresis. A dual channel Moor DT4 
laser Doppler flowmeter (Moor Instruments, England) was used 
TaBle 1 | Participant demographics, endothelial function and markers of 
vascular function prior to and following ssri therapy.
Baseline Post ssri P
Age (years) 43.9 ± 2.0
HAM-D 25 ± 1 8 ± 1 <0.001
BDI 29 ± 1 10 ± 1 <0.001
State 58 ± 2 38 ± 2 <0.001
Trait 64 ± 1 45 ± 2 <0.001
BMI (kg/m2) 26.0 ± 0.8 24.9 ± 0.8 0.06
Systolic BP (mmHg) 134 ± 2 133 ± 3 0.75
Diastolic BP (mmHg) 70 ± 2 69 ± 2 0.47
Heart rate (beats/min) 67 ± 2 64 ± 2 0.01
Plasma noradrenaline (pg/ml) 307 ± 42 201 ± 26 0.006
ICAM (ng/ml) 233 ± 15 234 ± 14 0.48
VCAM (ng/ml) 497 ± 26 483 ± 30 0.69
P-selectin (ng/ml) 56 ± 14 44 ± 7 0.40
Forearm blood flow (% change)
Endothelium dependent (% change) 1158 ± 122 1017 ± 163 0.43
Endothelium independent 1319 ± 417 1196 ± 177 0.9
Microiontophoresis (arbitrary units)
Acetylcholine 83 ± 16 81 ± 9 0.63
Sodium nitroprusside 91 ± 12 82 ± 11 0.56
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to measure erythrocyte flux. This was achieved using a helium–
neon infrared light from a laser, with a wavelength of 632.8 nm, 
via a fiber optic probe, which measures changes in the frequency 
shift that is produced by the scatter of photons from erythrocytes 
1–2 mm below the skin surface. The Doppler shift magnitude is 
directly proportional to erythrocyte flux (14). The subject was 
seated with his/her right arm extended across a hospital table, 
in a holding apparatus to eliminate arm movement, with the 
anterior surface facing the flowmeter. Polyvinyl chloride (PVC) 
chambers, specially made by us, with a central reservoir of 12 mm 
in diameter, or 0.5 ml volume, were placed on the forearm with 
double-stick disks (3M Health Care, ON, Canada). The chambers 
were positioned in a manner likely to avoid any apparent broken 
skin or hair growth. The subject was asked to sit in the same 
position for 10 min prior to, and throughout the procedure, to 
maintain basal blood flow levels in the vasculature. Assessment 
of erythrocyte flux was recorded on a computer using the Moor 
Instruments laser Doppler perfusion measurement package 
V3.01. Each of the 4 PVC chambers was scanned consecutively 
25 times over a period of approximately 7  min incorporating 
2 baseline scans, 30  s of perfusion, and the resultant vasodila-
tory response. Investigations of vascular endothelial function 
using this or similar procedures have traditionally utilized ACh 
to assess endothelium-dependent vasodilation and SNP for 
endothelium-independent vasodilation (15–18). ACh mediates 
endothelium-dependent vasodilation via interactions with nico-
tinic receptors present on endothelial cells. This results in NO 
release from the endothelium and subsequent vasodilatation. 
SNP is a nitric oxide donor that induces vasodilation by acting 
directly on the smooth muscle cells. Therefore, in the present 
study, endothelium-dependent vasodilation was measured by the 
iontophoresis of Ach (BDH Chemicals, UK) andendothelium-
independent vasodilation, the positive control, was assessed by 
the iontophoresis of SNP (Davis Bull Laboratories, Australia). 
Solutions of ACh and SNP were prepared, at least 24 h prior to the 
study, in methyl cellulose gel (10% w/v) (Sigma, MO, USA). To 
complete the circuit, a metal clip was placed onto a platinum wire, 
which lined the chamber interior on the skin/chamber interface. 
An iontophoresis controller provided a direct current for perfus-
ing the gel. An anodal current of 0.1 mA and a cathodal current 
of 0.1 mA were used to iontophorese ACh (10 mg/ml) and SNP 
(10 mg/ml), respectively, for 30 s. The speed with which a drug 
can be delivered is influenced by its molecular weight (19) and the 
degree of ionization of the drug (20). The coefficient of variation 
for measuring subcutaneous vascular reactivity determined by 
this method is 0.15 ± 0.05 (10). Responses to gel perfusion were 
measured as a frequency shift by the laser Doppler flowmeter 
and analyzed by the Moor Instruments laser Doppler perfusion 
computer package V3.01. The images displayed different colors, 
representing the degree of blood flux, on a scale of 250 U. Area 
under the curve was measured using Microsoft Excel (Microsoft 
Office 2000, Washington, DC, USA) to quantify each response. 
Data are represented as arbitrary perfusion units.
Following completion of the assessment of endothelial func-
tion an arterial line was placed aseptically in the brachial or radial 
artery by a cardiologist, as previously described (11). After at least 
20 min of supine rest, a blood sample (30 ml) was obtained for 
the determination of markers of vascular and platelet function, 
including noradrenaline, soluble P-selectin (P-selectin) soluble 
intercellular adhesion molecule-1 (ICAM-1), and soluble vascu-
lar cell adhesion molecule-1 (VCAM-1). Previous studies have 
demonstrated that elevated levels of these compounds may be 
independent risk factors for the development of atherosclerosis 
and CVD (21–23). The sample was collected in EDTA, lithium 
heparin, and EGTA-reduced glutathione tubes, stored on ice, 
centrifuged, and the plasma stored at −80°C until assayed. 
Noradrenaline was determined by high performance liquid chro-
matography with Coulometric detection, as previously described 
(24). Soluble P-selectin, ICAM, and VCAM were determined 
using commercially available kits (R&D Systems, Minneapolis, 
MN, USA) according to the manufacturer’s instructions.
statistical analyses
Statistical analysis was performed using IBM SPSS Statistics 
Version 22. Data are reported as mean ± SEM unless specified 
otherwise. Associations between variables were examined 
using Pearson’s product moment correlation coefficient and 
linear regression analysis. The effect of SSRI treatment was 
examined using a paired Student’s t-test. Non-Gaussian data 
were logarithmically transformed prior to analysis. A two-tailed 
value of P < 0.05 (with consideration of Bonferroni adjustment 
for multiple comparisons of biochemical variables) was deemed 
significant.
resUlTs
Demographic data, the level of depression and anxiety, and 
markers of endothelial and vascular function of participants 
are presented in Table  1. There was no difference in the level 
of depression or anxiety between genders and no association 
between age and BMI and the level of depression, as indicated 
February 2016 | Volume 7 | Article 184
Dawood et al. Endothelial Function in Depression
Frontiers in Psychiatry | www.frontiersin.org
from both the Hamilton and BDI scores. Older participants 
experienced a lower state anxiety level during the investigation 
(r = −0.49, P = 0.005). After controlling for age, there was a trend 
for an association between systolic blood pressure and state anxi-
ety (r = −0.33, P = 0.09). There occurred no association between 
the level of depression or anxiety and markers of vascular func-
tion. The levels of noradrenaline and P-selectin in plasma were 
positively linked (r = 0.83, P < 0.001).
Following SSRI therapy (95 ± 5 days), symptoms of depression 
and anxiety were markedly reduced (paired difference between 
pre- and post-treatment: Hamilton rating −18 ± 1, BDI −19 ± 2, 
trait anxiety −19 ± 2, state anxiety −19 ± 3, and all P < 0.001). 
Four participants did not return for the follow-up visit. Using 
standard cut offs for recovery and remission, that is, a 50% drop 
in Ham-D for remission, and a score of <8 in HAM-D to signify 
recovery, 19 were recovered, and 4 were remitted. The change in 
Ham-D was <50% in four participants.
Treatment with an SSRI did not significantly alter strain gage 
plethysmography determinations of endothelium-dependent 
(1017 ± 163% change from baseline, P = 0.43) or endothelium-
independent vasodilation (1196 ± 177% change from baseline, 
P = 0.9). Similarly, SSRI therapy did not significantly influence 
vascular response to iontophoretically administered ACh (81 ± 9 
arbitrary units) or SNP (82 ± 11 arbitrary units) in the forearm 
vasculature. Although the plasma noradrenaline concentration 
was reduced significantly following SSRI treatment (201 ± 26 pg/
ml, P =  0.006), there occurred no change in the plasma con-
centration of either of these, ICAM (234 ±  14  ng/ml), VCAM 
(483 ± 30 ng/ml), or P-selectin (44 ± 7 ng/ml), in response to 
SSRIs.
Participants who were recovered, with a Ham-D score 
<8 following SSRI therapy, had lower trait anxiety (62 ±  2 vs. 
66 ± 3, P = 0.02) and lower plasma noradrenaline concentration 
(245 ± 31 vs. 512 ± 136 pg/ml, P = 0.03) at baseline. There was a 
trend for plasma P-selectin to be higher in those subjects who did 
not respond as well to SSRI treatment (39.7 ± 3.3 vs. 95 ± 42 ng/
ml, P = 0.06). The change in Ham-D score was correlated with 
the baseline plasma noradrenaline concentration (r  =  −0.59, 
P = 0.003), P-selectin (r = −0.47, P = 0.02), and VCAM (−0.47, 
P = 0.02) concentrations and the change in plasma noradrenaline 
level after SSRI therapy (r = 0.44, P = 0.03). Similar findings were 
evident when the improvement in depression was estimated 
using % change in the Ham-D rating, with baseline trait anxiety 
(r = −0.42, P = 0.03), baseline plasma noradrenaline (r = −0.66, 
P = 0.001), and P-selectin (r = −0.53, P = 0.006) and change in 
plasma noradrenaline (r = 0.51, P = 0.01) being significant. Using 
forward stepwise multiple regression analysis, the change in 
Ham-D rating following SSRI treatment could be independently 
predicted by the baseline plasma noradrenaline concentration 
(r2 = 0.36, P = 0.003). We found no differential effect between 
citalopram and other SSRI medications on any of the parameters 
examined.
DiscUssiOn
We assessed endothelial function using the methods of strain gage 
plethysmography and LDV with direct current iontophoresis. 
Contrary to some previous reports, we found that antidepres-
sant therapy was not associated with any change in endothelial 
function or of markers of vascular function or platelet reactivity. 
Interestingly, there occurred a significant reduction in the plasma 
level of noradrenaline following SSRI treatment and that the 
improvement in Ham-D score following SSRI therapy was associ-
ated with the plasma noradrenaline level at baseline. Although 
the clinical significance of these findings remains uncertain, our 
observations do not support a role of endothelial dysfunction 
as an etiological factor in the increased cardiac risk associated 
with MDD.
There exist conflicting reports on endothelial function in 
patients with MDD (6, 7). Rajagopalan and colleagues docu-
mented endothelial dysfunction in young patients with depres-
sion (6), whereas Garcia et al. reported that endothelial function 
did not differ between young healthy subjects and patients with 
first onset depression, despite there occurring a reduced plasma 
level of metabolites of nitric oxide (7). In the present report, we 
found no change in measures of endothelial function in both 
the large vessels and resistance vessels following SSRI therapy. 
This observation contrasts with some reports that documented 
a worsening of endothelial function in patients with MDD 
following SSRI therapy (25). Broadley et  al. demonstrated that 
depressed patients undergoing effective therapy, in fact, displayed 
an impairment in endothelial function (25). Conversely, Hantsoo 
et  al. demonstrated that SSRI treatment exerted little effect on 
endothelial function or measures of platelet reactivity in women 
with depression (9). Whether the discordance between these 
results and ours is related to differences in medications used, 
severity of illness, or age and gender of participants remains 
unknown. Aging is associated with a progressive decline in 
endothelial function (26, 27) and gender, due at least in part to 
the difference in vessel size (28), and phase of the menstrual cycle 
(29, 30) has been shown to influence endothelial function.
We found no effect of SSRI therapy on the plasma level of 
ICAM, VCAM, or soluble P-selectin. Previous studies have 
indicated that patients with MDD may be susceptible to platelet 
activation, and possibly predisposing them to increased CVD 
risk (31). Whether the level of soluble P-selectin in plasma 
provides a reliable indicator of actual platelet activation may 
be open to question (32). Nevertheless, our observation of an 
association between plasma noradrenaline and P-selectin is 
intriguing. Elevated levels of noradrenaline in plasma enhance 
platelet aggregability and platelet secretion in  vivo in healthy 
humans (33). Whether heightened sympathetic nervous activ-
ity, which may be present in around one-third of patients with 
MDD (11), is associated with platelet reactivity deserves further 
attention. Of note also is our observation that baseline arterial 
plasma noradrenaline concentration predicted the improvement 
in depression following SSRI therapy. Although the majority of 
noradrenaline in plasma is derived from sympathetic nerves, it 
is important to note that the sympathetic nervous system is of 
course regulated centrally. Determining the central determinants 
of high sympathetic tone in patients with MDD may give insight 
into the neuropathology underlying the condition.
There are a number of limitations to our study which should 
be noted. We did not include a placebo control group as we 
February 2016 | Volume 7 | Article 185
Dawood et al. Endothelial Function in Depression
Frontiers in Psychiatry | www.frontiersin.org
thought it unethical to withhold therapy from significantly ill 
individuals. Hence, it remains unknown whether our patients, 
in fact, displayed signs of endothelial dysfunction prior to 
therapy. Although we did not measure levels of ICAM, VCAM, 
or P-selectin in healthy subjects, the concentrations determined 
seem to be in the range reported for control subjects by others 
(21, 34, 35). It is perhaps not surprising therefore that SSRI 
therapy was without an effect on these parameters. Endothelial 
function was assessed using two methods, flow-mediated dila-
tation in response to reactive hyperemia and LDV with direct 
current iontophoresis. Although these methods are widely used, 
particularly in cardiovascular research, gold standard methods 
typically involve intracoronary or intrabrachial arterial infusion 
of vasoactive substances (36).
In conclusion, examination of endothelial function, deter-
mined by plethysmography of the forearm and LDV, did not 
reveal differences between endothelium-dependent blood flow 
and endothelium-independent blood flow in patients with MDD 
prior to or following SSRI treatment. We found no effect of SSRI 
therapy on the plasma level of ICAM, VCAM, or P-selectin. The 
baseline arterial plasma noradrenaline level was predictive of the 
improvement in severity of depression following SSRI treatment. 
Whether endothelial dysfunction is impaired and is associated 
with increased cardiac risk in patients with MDD remains 
unknown.
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